Inebilizumab cut MG exacerbations and rescue therapy use in MINT, and a post hoc analysis found similar responses regardless ...
Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure ...
The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...
FDA approves dexmedetomidine sublingual film for at-home use in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
The UCSF Health–based leukemia and lymphoma specialist outlines chemo-free DLBCL, dual-targeted CAR T-cell therapy, and MRD-guided deescalation.
In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.
Lead VERIFY trial investigator Andrew Kuykendall, MD, explains how rusfertide could replace phlebotomy and ease fatigue in ...
Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
In 2024, physicians face significant financial challenges due to declining Medicare reimbursement rates and high student loan interest rates, which will impact health care delivery and access. In 2024 ...
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 ...
T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment ...